Results 91 to 100 of about 182,500 (270)

Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial

open access: yesBMJ Open, 2020
Background Pembrolizumab was recently demonstrated to have survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma (r/mHNSCC).
Haiying Ding   +6 more
doaj   +1 more source

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma

open access: yes, 2019
Junichi Inokuchi, Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: The prognosis of patients with unresectable or metastatic urothelial carcinoma (UC) is poor. Platinum-based chemotherapy
Inokuchi J, Eto M
core  

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data

open access: yes, 2019
Pauline du Rusquec, Ombline de Calbiac, Marie Robert, Mario Campone, Jean Sebastien FrenelMedical Oncology Department, Institut de Cancérologie de l’Ouest, Saint-Herblain 44800, FranceAbstract: Pembrolizumab is a full-length human ...
Campone M   +4 more
core  

Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma

open access: yes
Background: Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in advanced disease.
Miyake, Hideaki   +26 more
core   +1 more source

A Case of Pembrolizumab Induced Papillitis With Transverse Myelitis

open access: yes, 2021
Pembrolizumab is a humanized monoclonal antibody that inhibits programmed cell death-1 (PD-1) pathway resulting in an enhanced immune response. Currently, pembrolizumab is an approved treatment for cutaneous melanoma. Very few patients (
Ragha Chaitanya Sakuru; Merati Melody; Nathan Lambert-Cheatham; Sophia Tessema; Luke Salbert; Lina Nagia
core  

Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence

open access: yes, 2022
The recent introduction of immunotherapy in the first line setting of advanced renal cell carcinoma (aRCC) has dramatically improved patients' prognosis.
Capitanio, Umberto   +12 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

open access: yesFrontiers in Oncology
BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated.
Wei Chen   +8 more
doaj   +1 more source

Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials

open access: yes, 2017
Manni Wang,* Xuelei Ma,* Linghong Guo, Fan Xia State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China *These authors contributed equally to this work Background ...
Guo LH, Ma XL, Wang MN, Xia F
core  

Home - About - Disclaimer - Privacy